BrainChip Holdings reported a net loss of $12.0 million for the half-year ended 30 June 2026, compared to $9.4 million in the prior year, as the neuromorphic AI processor company entered a significant investment phase to bring its next generation products to market.
The company’s revenue rose 19% to $1.22 million from $1.02 million, a gain that warrants closer examination. For the first time, BrainChip generated $613,826 in license sales, signalling the beginning of meaningful commercialization of its Akida neuromorphic technology. Product sales grew to $110,362 from $19,184, though development services revenue declined to $498,557 from $1.0 million.
The real story lies in spending patterns. Operating expenses jumped 33% to $13.6 million from $10.3 million, driven largely by research and development investment of $5.5 million, a 61% increase from $3.4 million in the prior half-year. The company attributed this increase to development of its AKD2500 chip, which cost $1.3 million during the period, along with a 22% increase in employee costs following a merit pay increase in April 2026. Software licensing and hardware expenses also increased across the R&D function.
Selling and marketing expenses grew a more modest 16% to $2.6 million from $2.2 million. The pronounced gap between revenue growth and expense growth tells a critical story about company strategy. BrainChip is operating in a heavy investment phase, betting that commercialization of its AKD1500 and the subsequent development of Akida 2.0 will generate substantial revenue growth in 2027 and beyond. This is a familiar pattern for hardware and deep technology companies attempting to scale from research and development into full commercialization.
The emergence of license revenue deserves particular attention. Licensing deals for specialized processors typically carry higher profit margins and suggest genuine customer adoption and technical validation. These contracts represent recurring or milestone-based revenue streams that provide greater visibility than one-off product sales. However, at $613,826 for the half-year, license revenue remains small relative to the company’s total investment.
BrainChip’s operational trajectory remains challenging for investors. The company is burning cash at a significant rate, and continued losses of $12 million per half-year will warrant close attention to available cash reserves and funding runway. Chip development and commercialization are capital-intensive activities, and BrainChip operates in a competitive landscape where larger semiconductor and AI companies possess greater financial resources.
For investors, the key metric is execution. BrainChip must demonstrate that its upcoming product launches and licensing partnerships can accelerate revenue growth sufficiently to offset current spending and justify the investment strategy. The half-year report confirms the company remains committed to this path. Monitoring quarterly revenue trends, particularly growth in license sales and customer announcements related to new products, will be essential to assessing whether the strategy is delivering results. This announcement has been flagged as price sensitive and material by the ASX.
View the full ASX announcement (PDF)
About BrainChip Holdings Limited (ASX: BRN)
BrainChip is an Australian technology company that develops neuromorphic artificial intelligence hardware and software solutions for edge computing applications. The company’s core products include the Akida neuromorphic processor, which mimics the human brain’s neural architecture to deliver ultra-low power AI processing, and MetaTF software for developing and training neural networks. BrainChip serves markets in North America, Europe, Asia, and the Middle East, targeting applications in security, surveillance, autonomous vehicles, and industrial automation.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
